본문 바로가기

Clinicopathological Reclassification of Idiopathic Inflammatory Myopathy to Match the Serological Results of Myositis-Specific Antibodies

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2KCI Q2
저널
JOURNAL OF CLINICAL NEUROLOGY20(1) · pp.67 · 2024
피인용
Web of Science 2Scopus 3KCI 1
FWCI (Scopus)
0.45
JCR IF
JCR 2023 3
ISSN
1738-6586

저자

  1. 박영은제1저자Pusan Natl Univ Hosp, Dept Neurol, PusanBusan, South Korea
  2. 김대성Pusan Natl Univ, Yangsan Hosp, Dept Neurol, Yangsan, South Korea
  3. Kang, MinsungKyungpool Natl Univ, Chilgok Hosp, Dept Neurol, Daegu, South Korea
  4. 신진홍교신저자Pusan Natl Univ, Yangsan Hosp, Dept Neurol, Yangsan, South Korea

초록

Background and Purpose Advances in serological tests are transforming the classification of idiopathic inflammatory myopathy (IIM). The new criteria suggested by the 119th European Neuromuscular Center international workshop divide IIM cases into four main diseases according to clinical and pathological findings, adding immune-mediated necrotizing myositis and nonspecific myositis to the classic categories of polymyositis and dermatomyositis. Methods Seventy one cases of IIM with sufficient available clinical and pathological data were reviewed to be reclassified according to the new criteria. Results Most of the cases previously classified as polymyositis (77.8%, 35/45) were reclassified as immune-mediated necrotizing myopathy. The results of myositis-specific antibodies matched well with the new clinicopathological classification. Conclusions This new clinicopathological classification for IIM in combination with serological test results could be applied to our previous case series. Adoption of the new criteria will lead to a better understanding of the disease and hence new therapeutic insights.

키워드

classificationdermatomyositismyositispolymyositisserologyWORKSHOP PATHOLOGY DIAGNOSISPOLYMYOSITISNAARDEN

식별자

Scopus EID
2-s2.0-85182397863
WoS UID
001140304100008
KCI
ART003025913